New systemic therapies have revolutionized the treatment of advanced basal cell carcinoma (BCC). In this activity, a skin cancer specialist explains the mechanisms of action and appropriate use for hedgehog pathway inhibitors and the recently approved therapy cemiplimab. The case-based discussion illustrates treatment decision points and management of side effects associated with systemic therapies, with a focus on education of patients and caregivers.
Interactive video lecture
After completing this activity, participants should be better able to:
- Describe the mechanism of action for new systemic therapies for the treatment of advanced BCC
- Identify newly available and emerging therapies for advanced BCC and their appropriate use in clinical practice
- Implement strategies to recognize and appropriately manage side effects associated with novel therapies for advanced BCC
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until July 29, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Madden: consulting fees: Novartis.
Dr Pavlick: contracted research/consulting fees: Bristol Myers Squibb, Merck, Regeneron; consulting fees: Replimune.
None of the members of the planning committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hours.
Release date: July 30, 2021
Expiration date: July 29, 2022
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 100721O-7B